E3K CAR-T cells

N/A

Report date: 2025/06/11 10:41:58

Base Information

Drug NameE3K CAR-T cells

Drug Alias Nameanti-CD248 E3K CAR-T cell therapy (Institute of Cancer research/University of Lausanne/University of Birmingham/University of Manchester)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsEndosialin modulatorsT lymphocytes stimulants

TargetsEndosialin

Therapy Area/IndicationsSolid tumoursLung NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Of Cancer Research

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Of Cancer Research University Of Lausanne University Of Birmingham +[4]

Inactive CompaniesN/A

Active IndicationsSolid tumoursLung NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A